Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin trihydrate - powder for oral suspension - 3gram

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - colestyramine anhydrous - powder for oral suspension - 4gram

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - colestyramine anhydrous - powder for oral suspension - 4gram

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefazolin sodium, quantity: 2096 mg (equivalent: cefazolin, qty 2000 mg) - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present. genitourinary tract infections due to e. coli, p. mirabilis, and klebsiella sp. and some strains of enterobacter and enterococci. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resisant) and group a beta-haemolytic streptococci and other strains of streptococci. bone and joint infections due to staph. aureus. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), e. coli, p. mirabilis, and klebsiella sp. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. note: appropriate culture and susceptibility studies should be preformed to determine susceptibility of the causative organism to cephazolin.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Storbritannien - engelska - VMD (Veterinary Medicines Directorate)

dechra veterinary products a/s - phenylbutazone - oral powder - anti inflammatory nsaid - horses

Irland - engelska - HPRA (Health Products Regulatory Authority)

dechra ltd - phenylbutazone - oral powder - 1.0 gram(s) - phenylbutazone - non food-producing horses - n.s.a.i.d.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - recombinant cholera toxin b subunit 1mg; vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated); vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated); vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) - oral suspension - active: recombinant cholera toxin b subunit 1mg vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated) vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated) vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate dihydrate citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate - active immunisation of adults and children from two years of age, who will be visiting areas with an ongoing or anticipated epidemic or who will be spending an extended period of time in areas in which cholera infection is a risk. the vaccine should be considered for foreign aid workers and others intending to visit or spend an extended period of time in areas endemic or epidemic for cholera.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; sorbitol; saccharin sodium; colloidal anhydrous silica; sodium benzoate; xanthan gum; disodium edetate; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 28.7 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; disodium edetate; xanthan gum; saccharin sodium; sodium benzoate; sorbitol; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis